Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOVIN-II: continue letrozole versus switch to gonadotropins in ovulatory PCOS
NL-OMON60859Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of letrozole in polycystic ovary syndrome (PCOS) and female infertility (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Pregnancy leading to live birth within 8 months after randomization. Started Aug 2025; status: recruiting.
02
Drugs
letrozole
03
Conditions
polycystic ovary syndrome (PCOS)female infertility
Beyond the preview
Go deeper on NL-OMON60859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60859.